Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer

References

• Bethesda M. SEER cancer stat facts: bladder cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/urinb.html, based on November 2017.
   Google Scholar
• National Cancer Institute Seer cancer statistics review. 2005. p. 1992–2013. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/.
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.
   Google Scholar
• Compérat E, Larré S, Roupret M, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015;466(5):589–594.
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2016;71:447–461.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guerin. Eur Urol. 2016;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Van Der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–475.
   PubMed Web of Science ®Google Scholar
• Kwon GY, Ro JY. Micropapillary variant of urothelial carcinoma. Adv Urol 2011; 2011:217153. doi: 10.1155/2011/217153.
   Google Scholar
• Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155(4):1233–1238.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with Stage pTa-pT1 urothelial carcinoma. Eur Urol. 2015;69:2.
   Web of Science ®Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.
   PubMed Web of Science ®Google Scholar
• Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2016 May;197(5):89–99.
   Web of Science ®Google Scholar
• Ali-El-Dein B, El-Baz M, Aly ANM, et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol. 1997 Jul 1;158(1):68–74.
   PubMed Web of Science ®Google Scholar
• Perlis N, Zlotta AR, Beyene J, et al. Immediate post–transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013 Sep;64(3):421–430.
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203.
   PubMed Web of Science ®Google Scholar
• Abern MR, Owusu RA, Anderson MR, et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Cancer Network. 2013;11(4):477–484.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53(4):709–719.
   PubMed Web of Science ®Google Scholar
• Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol. 2000;53(7):676–680.
   PubMed Web of Science ®Google Scholar
• Oddens JR, Sylvester RJ, Brausi MA, et al. The effect of age on the efficacy of maintenance Bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014;66(4):694–701.
   PubMed Web of Science ®Google Scholar
• Sinn HW, Elzey BD, Jensen RJ, et al. The fibronectin attachment protein of Bacillus Calmette-Guerin (BCG) mediates antitumor activity. Cancer Immunol Immunother. 2008;57(4):573–579.
   PubMed Web of Science ®Google Scholar
• Pook S-H, Rahmat JNB, Esuvaranathan K, et al. Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic. Oncol Rep. 2007;18(5):1315–1320.
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical Bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–1223.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical Bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–216.
   PubMed Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–95.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Van Der MEIJDEN APM, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(November):1964–1970.
   PubMedGoogle Scholar
• Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl. 2008;7(10):667–674.
   Web of Science ®Google Scholar
• Ahn JJ, Ghandour RA, McKiernan JM. New agents for Bacillus Calmette-Guérin-refractory nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24(5):540–545.
   PubMed Web of Science ®Google Scholar
• Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Guréin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1915–1919.
   PubMed Web of Science ®Google Scholar
• Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: international consensus panel. Urology. 2005;66(6 SUPPL. 1):108–125.
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472.
   PubMed Web of Science ®Google Scholar
• Martínez-Piñeiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89(7):671–680.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016;34(16):1935–1944.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109(4):496–505.
   PubMed Web of Science ®Google Scholar
• Bendary L, Khalil S, Shahin A, et al. 1655 intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study. J Urol. 2011;185(4):e664–5.
   Web of Science ®Google Scholar
• Porena M, Del Zingaro M, Lazzeri M, et al. Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int. 2010;84(1):23–27.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus Bacille Calmette-Guérin after initial Bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893–1900.
   PubMed Web of Science ®Google Scholar
• Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1(1):CD009294.
   PubMedGoogle Scholar
• Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010;22(3):242–249.
   PubMed Web of Science ®Google Scholar
• Dinney CPN, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after Bacillus Calmette-Guerin. Urol Oncol Semin Orig Investig. 2013;31(8):1635–1642.
   PubMed Web of Science ®Google Scholar
• Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. Valrubicin Study Group J Urol. 2000;163(3):761–767.
   Web of Science ®Google Scholar
• Hendricksen K, Van Der Heijden AG, Cornel EB, et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009;27(3):337–342.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Cornel EB, De Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol. 2012;187(4):1195–1199.
   PubMed Web of Science ®Google Scholar
• Hancock BM, Mcguire KL, Tsuji S, et al. A single intravesical instillation of VAX014 inhibits orthotopic superficial bladder tumor implantation to increase survival. Anticancer Res. 2016;36(12):6243–6248.
   PubMed Web of Science ®Google Scholar
• Liem EIML, Crezee H, De La Rosette JJ, et al. Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperth. 2016;6736:(April):1–11.
   Google Scholar
• Zargar H, Aning J, Ischia J, et al. Optimizing intravesical mitomycin C therapy in nonmuscle-invasive bladder cancer. Nat Rev Urol. 11:220–230.
   PubMed Web of Science ®Google Scholar
• Arends TJH, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918.
   PubMed Web of Science ®Google Scholar
• Arends TJH, Van Der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192(3):708–713.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Wientjes MG, Badalament RA, et al. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 1991;51(15):3849–3856.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12(9):871–879.
   PubMed Web of Science ®Google Scholar
• Gan C, Amery S, Chatterton K, et al. Sequential Bacillus Calmette-Guérin/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J Urol. 2016;195(6):1697–1703.
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Nepple KG. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin. Urol Oncol Semin Orig Investig. 2016;34(6):279–289.
   PubMed Web of Science ®Google Scholar
• Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 2005;4(3):283–293.
   PubMed Web of Science ®Google Scholar
• Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 2001 Jun cited 2017 Aug 12;165(6 Pt 1):1904–1907.
   PubMed Web of Science ®Google Scholar
• Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology. 2003;61(2):338–341.
   PubMed Web of Science ®Google Scholar
• Filonenko EV, Kaprin AD, Alekseev BYA, et al. 5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial). Photodiagnosis Photodyn Ther. 2016;16:106–109.
   PubMed Web of Science ®Google Scholar
• Yaman Ö, Özdiler E, Sözen S, et al. Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model. Int J Urol. 1999;6(2):87–92.
   PubMed Web of Science ®Google Scholar
• Chen D, Song D, Wientjes MG, et al. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res. 2003;9(1I):363–369.
   PubMedGoogle Scholar
• Au JL-S, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604.
   PubMed Web of Science ®Google Scholar
• Huang W, Wang F, Wu C, et al. Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study. Int Urol Nephrol. 2015;47(4):631–636.
   PubMed Web of Science ®Google Scholar
• Topazio L, Miano R, Maurelli V, et al. Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study. BMC Urol. 2014;14:64.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Li Z, Chancellor M, et al. Using thermosensitive hydrogel. Animals. 2004;21(5):832–837.
   Google Scholar
• Lopedota A, Cutrignelli A, Laquintana V, et al. Spray dried chitosan microparticles for intravesical delivery of celecoxib: preparation and characterization. Pharm Res. 2016;33(9):2195–2208.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Kirby JA, Davies BR, et al. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol. 2008;54(3):621–630.
   PubMed Web of Science ®Google Scholar
• Denora N, Lopedota A, Perrone M, et al. Spray-dried mucoadhesives for intravesical drug delivery using N-acetylcysteine- and glutathione-glycol chitosan conjugates. Acta Biomater. 2016;43:170–184.
   PubMed Web of Science ®Google Scholar
• Mun EA, Williams AC, Khutoryanskiy VV. Adhesion of thiolated silica nanoparticles to urinary bladder mucosa: effects of PEGylation, thiol content and particle size. Int J Pharm. 2016;512(1):32–38.
   PubMedGoogle Scholar
• Nakamura T, Noma Y, Sakurai Y, et al. Modifying cationic liposomes with cholesteryl-peg prevents their aggregation in human urine and enhances cellular uptake by bladder cancer cells. Biol Pharm Bull. 2017;40(2):234–237.
   PubMed Web of Science ®Google Scholar
• Lu S, Xu L, Kang ET, et al. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. Eur J Pharm Sci. 2016;84:103–115.
   PubMed Web of Science ®Google Scholar
• Jin X, Ma J, Liang X, et al. Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway. Biomaterials. 2017;113:93–104.
   PubMed Web of Science ®Google Scholar
• Rajala P, Kaasinen E, Raitanen M, et al. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study – Finnbladder III long-term results. J Urol. 2002;168(3):981–985.
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination Bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer{star, open}. Urol Oncol Semin Orig Investig. 2006;24(4SPEC. ISS.):344–348.
   PubMedGoogle Scholar
• Morales A, Cohen Z. Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin. Expert Opin Biol Ther. 2016;16(2):273–283.
   PubMed Web of Science ®Google Scholar
• Dinney CPN, Fisher MB, Navai N, et al. Phase i trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190(3):850–856.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Sheinin Y, Crispen PL, et al. T-Cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800–4808.
   PubMed Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–1505.
   PubMed Web of Science ®Google Scholar
• Lerner SP, Bajorin DF, Dinney CP, et al. Summary and recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on novel therapeutics for non-muscle invasive bladder cancer. Bl Cancer. 2016;2(2):165–202.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017 Feb;18(2):212–220.
   PubMed Web of Science ®Google Scholar
• Gupta S, Gill D, Poole A, et al. Systemic immunotherapy for urothelial cancer: current trends and future directions. Cancers (Basel). 2017;9(2):15.
   Web of Science ®Google Scholar